FDA Approves Clinical Trial Of Incannex's Dronabinol-Based Drug For Obstructive Sleep Apnea
Portfolio Pulse from Vuk Zdinjak
Incannex Healthcare Limited (NASDAQ:IXHL) has received approval from the US Food and Drug Administration to conduct the company’s investigational new drug (‘IND’) opening pivotal IHL-42X phase 2/3 clinical trial in the United States. The IND opening trial will assess the effect of IHL-42X in obstructive sleep apnea patients who are non-compliant, intolerant, or naïve to positive airway pressure treatment.
August 22, 2023 | 12:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Incannex Healthcare's stock may see a positive impact due to the FDA approval for the phase 2/3 clinical trial of its new drug IHL-42X. This approval is a significant milestone for the company and could potentially lead to increased investor confidence.
FDA approval for clinical trials is a significant milestone for any healthcare company. This approval indicates that the FDA believes the drug has potential and is safe to proceed to the next phase of testing. This could lead to increased investor confidence in Incannex Healthcare and potentially a rise in its stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100